1. Home
  2. BFS vs NRIX Comparison

BFS vs NRIX Comparison

Compare BFS & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BFS
  • NRIX
  • Stock Information
  • Founded
  • BFS 1993
  • NRIX 2009
  • Country
  • BFS United States
  • NRIX United States
  • Employees
  • BFS N/A
  • NRIX N/A
  • Industry
  • BFS Real Estate Investment Trusts
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BFS Real Estate
  • NRIX Health Care
  • Exchange
  • BFS Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • BFS 770.5M
  • NRIX 750.4M
  • IPO Year
  • BFS 1993
  • NRIX 2020
  • Fundamental
  • Price
  • BFS $29.98
  • NRIX $9.82
  • Analyst Decision
  • BFS
  • NRIX Strong Buy
  • Analyst Count
  • BFS 0
  • NRIX 14
  • Target Price
  • BFS N/A
  • NRIX $28.14
  • AVG Volume (30 Days)
  • BFS 76.3K
  • NRIX 1.2M
  • Earning Date
  • BFS 11-06-2025
  • NRIX 10-09-2025
  • Dividend Yield
  • BFS 7.87%
  • NRIX N/A
  • EPS Growth
  • BFS N/A
  • NRIX N/A
  • EPS
  • BFS 1.32
  • NRIX N/A
  • Revenue
  • BFS $277,902,000.00
  • NRIX $83,687,000.00
  • Revenue This Year
  • BFS $6.92
  • NRIX $78.20
  • Revenue Next Year
  • BFS $4.90
  • NRIX N/A
  • P/E Ratio
  • BFS $22.72
  • NRIX N/A
  • Revenue Growth
  • BFS 5.23
  • NRIX 48.32
  • 52 Week Low
  • BFS $29.83
  • NRIX $8.18
  • 52 Week High
  • BFS $42.39
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • BFS 29.42
  • NRIX 52.20
  • Support Level
  • BFS $29.97
  • NRIX $9.00
  • Resistance Level
  • BFS $30.75
  • NRIX $10.85
  • Average True Range (ATR)
  • BFS 0.53
  • NRIX 0.68
  • MACD
  • BFS -0.09
  • NRIX 0.12
  • Stochastic Oscillator
  • BFS 3.08
  • NRIX 60.75

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: